Summary
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
History
Aclaris Therapeutics was founded in 2013 by Neal Walker and Robert Megalla. The company's first product, the over-the-counter topical dandruff shampoo, was released in January 2015. Since then, the company has grownits product portfolio to include other dermatological treatments, treatments for alopecia areata, Ivermectin cream and a foray into hair growth stimulators.
Mission
Aclaris' mission is to identify, develop, and commercialize innovative and effective ways to improve the lives of patients in need.
Vision
Aclaris' vision is to become a global biopharmaceutical company with a focus on developing treatments for immuno-inflammatory disorders, dermatological and aesthetic conditions, and other diseases. We strive to be a premier provider of health solutions, leveraging cutting-edge science to bring new therapies and products to patients worldwide.
Key Team
Dr. Douglas J. Manion Frcp(C), M.D. (Pres & COO)
Mr. Robert A. Doody Jr. (VP of Investor Relations)
Mr. Matthew Rothman J.D. (Gen. Counsel & Corp. Sec.)
Dr. Jon Jacobsen Ph.D. (Sr. VP of Chemistry)
Dr. Paul S. Changelian Ph.D. (Sr. VP of Biology)
Mr. James Loerop (Chief Bus. Officer)
Dr. Ian Anderson Ph.D. (Exec. VP of Translational R&D)
Recognition and Awards
Aclaris has been recognized for its commitment to innovation, performance and patient-centricity, winning the Red Herring Global Top 100 in 2017, the Frost and Sullivan North American Company of the Year in Dermatology in 2018 and the BioNJ Impact Award in recognition of their delivery of Ivermectin Cream in 2019.
References
United States 